Emily Woolley

Senior Director, Biostatistics

Emily Woolley is Senior Director, Biostatistics at Axio, a Cytel Company. Emily leads the global DMC biostatistics team and has been with the organization for 10 years. Emily helps oversee the day-to-day operations of the DMC business including project oversight, delivery, quality, and finances. Emily manages a team of direct and indirect reports who serve as Independent Statisticians to DMCs. Emily has also served as the lead biostatistician for several successful regulatory submissions.

Emily enjoys mentoring team members in statistics and business management, building client relationships, continued process improvement, and showcasing Axio’s DMC services.

Emily has a MS degree in Statistics and lives in Bend, Oregon.

Emily Woolley

Related Articles

Regulatory Guidance on Patient-Centric DMC Risk-Benefit Assessments
Blog
November 25, 2025
Regulatory Guidance on Patient-Centric DMC Risk-Benefit Assessments
Read More
Setting Expectations for Formal Interim Analyses with Independent Data Monitoring Committees
Blog
September 13, 2023
Setting Expectations for Formal Interim Analyses with Independent Data Monitoring Committees
Read More
Preserving Trial Integrity After Receiving an Unanticipated IDMC Recommendation
Blog
December 4, 2023
Preserving Trial Integrity After Receiving an Unanticipated IDMC Recommendation
Read More
Reducing Independent Data Monitoring Committee Timelines: A Focus on Formal Interim Analyses
Blog
September 25, 2023
Reducing Independent Data Monitoring Committee Timelines: A Focus on Formal Interim Analyses
Read More